PolarityTE Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • PolarityTE's estimated annual revenue is currently $1.6M per year.(i)
  • PolarityTE received $17.8M in venture funding in September 2017.
  • PolarityTE's estimated revenue per employee is $22,014
  • PolarityTE's total funding is $17.8M.

Employee Data

  • PolarityTE has 71 Employees.(i)
  • PolarityTE grew their employee count by -24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

PolarityTE (NASDAQ: COOL) is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





PolarityTE News

2022-04-17 - PolarityTE, Inc. (NASDAQ:PTE) Expected to Announce ...

Equities research analysts expect that PolarityTE, Inc. (NASDAQ:PTE – Get Rating) will report ($0.08) earnings per share (EPS) for the...

2022-04-06 - Thinking about buying stock in Polarityte, RLX Technology ...

Thinking about buying stock in Polarityte, RLX Technology, Bitnile, Aterian, or Cyclacel Pharmaceuticals? InvestorsObserver (PRNewsfoto/...

2022-03-22 - PolarityTE, Inc. (PTE) CEO Richard Hague On Q4 2021 Results - Earnings Call Transcript

PolarityTE, Inc. (NASDAQ:PTE) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET. Company Participants.

2019-09-09 - SkinTE Data to be Presented at the American Society of ...

SALT LAKE CITY, Sept. 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing ...

2019-08-28 - PolarityTE to Attend HC Wainwright 21st Annual Healthcare ...

SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

PolarityTE Funding

DateAmountRoundLead InvestorsReference
2017-09-22$17.8MUndisclosedCantor FitzgeraldArticle